Please ensure Javascript is enabled for purposes of website accessibility

Why Shares in Antares Pharma, Inc. Burst Today

By Todd Campbell - May 6, 2015 at 12:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Antares Pharma, Inc. shares tumbled after it priced its secondary stock offering.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Source: Antares Pharma,

What: Shares in Antares Pharma (ATRS) slumped by 10% earlier today after it priced a dilutive secondary stock offering.

So What: Antares Pharma is offering to sell 20 million shares at a price of $2 per share in a bid to raise $37.6 million, after fees and commissions are paid to brokers and advisors.

The company plans to use the proceeds from this secondary offering to support its business development, in-licensing, and acquisition efforts.

Those efforts will likely include increased marketing for Otrexup, a treatment that is approved to treat adults with severe active rheumatoid arthritis and in children with active polyarticular juvenile idiopathic arthritis.

In April, Antares Pharma got back rights from LEO Pharma A/S to market Otrexup to dermatologists for use in treating severe recalcitrant psoriasis. Although dermatologists account for less than 5% of Otrexup's current script volume, Antares Pharma believes there's still an opportunity to market to these prescribers and increase Otrexup's sales.

Antares Pharma is also developing a once-weekly Quickshot testosterone injector for patients on testosterone replacement therapy and, despite receiving a complete response letter from the FDA denying approval of its Vibex sumatriptan for use in migraine patients, the company continues to pursue that therapy with partner Teva Pharmaceuticals.

Now What: Antares Pharma is focusing its efforts on partnering with specialty pharmaceutical companies that want to use Antares Pharma's injection technology to administer their medications. If the company is successful in this strategy, it should provide a steady stream of upfront, milestone, and royalty payments that can complement sales of its wholly owned products, such as Otrexup.

So far, its strategy appears to be working. In the fourth quarter, Antares Pharma reported sales of $8.4 million, up 77% year-over-year, and as a result, its net loss shrank to $0.08 in the quarter from $0.27 the year before.

Since the company is sitting on $40 million in cash already, and it doesn't have any debt, the additional money from this offering should give it plenty of financial flexibility; however, this is a small cap stock that's still losing money and for that reason, I'm unwilling to take on the risk of owning this one in my portfolio.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Antares Pharma, Inc. Stock Quote
Antares Pharma, Inc.
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
$7.83 (-4.63%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.